Researchers determined that ivermectin had no significant impact on preventing COVID-19 patients from being admitted to the hospital in a recent study presenting the findings of a randomized-controlled trial.
Since the start of the SARS-COV-2 outbreak, ivermectin has attracted people’s attention. Ivermectin is an antiparasitic medication that has been designated as an essential drug by the World Health Organization (WHO) for the treatment of certain parasitic diseases. It has also shown antiviral efficacy against a certain set of viruses.
The evidence provided by the current body of research regarding ivermectin’s efficacy as a pharmaceutical treatment for COVID-19 remains unclear.
In a new paper reporting the results of a randomized-controlled trial, researchers found ivermectin had no effect in preventing COVID-19 patients from being admitted to the hospital. In fact, the paper reports that ivermectin-treated patients needed invasive mechanical ventilatory support (MVS) sooner in their treatment.
The paper’s results state, “Of all the individuals who participated in the study, 35 (6.99%) required hospitalization at any point from randomization to their end of study visit. Of these, 14 (5.60%) belonged to the ivermectin group and 21 (8.37%) to the placebo group. There were no statistically significant differences between the two groups.”
It’s important to note that out of the patients who were given the ivermectin treatment, none of them experienced any serious side-effects.
“Finally, when analyzing the ivermectin safety point in terms of its adverse events, no per protocol serious adverse events were observed during the study,” the authors stated. “Non-serious adverse events occurred in 79 patients (15.77%) of the 501 participants, with a total of 98 non-serious adverse events distributed in 45 events (18.00%) in the ivermectin group and 53 events (21.11%) in the placebo group. None of the patients discontinued study medication because of adverse events.”
The study consisted of a randomized, double-blind, placebo-controlled trial. Daily telephone contact was used to collect data on the patients’ medical history, COVID-19-related symptoms, daily progress, and adverse events during their trial participation.
Patients were divided into subgroups based on whether they were symptomatic or asymptomatic, their age (65 years or 65 years), and the length of their symptoms previous to enrollment in the research (seven days or seven days) among symptomatic patients. Patients were evaluated according to which group they were allocated during randomization, regardless of whether they afterwards got ivermectin or placebo, or whether they failed to adhere to treatment compliance.
A recent report from the Pan American Health Organization (PAHO) on the various treatments for the treatment of COVID also found no significant reduction in hospitalizations of individuals with mild to moderate COVID-19 who were treated with ivermectin in a meta-analysis that included 4837 patients.
This is the first peer-reviewed, randomized, double-blind, placebo-controlled study on the effectiveness of ivermectin in avoiding hospitalizations.
The study was published BMC Infectious Diseases, on July 2nd, 2021.
Results. The mean age was 42 years (SD ± 15.5) and the median time since symptom onset to the inclusion was 4 days [interquartile range 3-6]. The primary outcome of hospitalization was met in 14/250 (5.6%) individuals in ivermectin group and 21/251 (8.4%) in placebo group (odds ratio 0.65; 95% confidence interval, 0.32-1.31; p = 0.227). Time to hospitalization was not statistically different between groups. The mean time from study enrollment to invasive mechanical ventilatory support (MVS) was 5.25 days (SD ± 1.71) in ivermectin group and 10 days (SD ± 2) in placebo group, (p = 0.019). There were no statistically significant differences in the other secondary outcomes including polymerase chain reaction test negativity and safety outcomes.